1. Home
  2. SBGI vs CSTL Comparison

SBGI vs CSTL Comparison

Compare SBGI & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sinclair Inc.

SBGI

Sinclair Inc.

N/A

Current Price

$14.83

Market Cap

883.7M

Sector

Industrials

ML Signal

N/A

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

N/A

Current Price

$34.32

Market Cap

722.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SBGI
CSTL
Founded
1986
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
883.7M
722.8M
IPO Year
2023
2019

Fundamental Metrics

Financial Performance
Metric
SBGI
CSTL
Price
$14.83
$34.32
Analyst Decision
Hold
Strong Buy
Analyst Count
7
9
Target Price
$17.64
★ $48.20
AVG Volume (30 Days)
★ 728.9K
377.1K
Earning Date
11-04-2026
11-05-2026
Dividend Yield
★ 6.67%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $3,169,000,000.00
$344,229,000.00
Revenue This Year
$11.93
$12.74
Revenue Next Year
N/A
$11.78
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 3.66
52 Week Low
$11.83
$17.72
52 Week High
$17.88
$44.28

Technical Indicators

Market Signals
Indicator
SBGI
CSTL
Relative Strength Index (RSI) 62.77 49.11
Support Level $12.93 $33.90
Resistance Level $15.94 $34.23
Average True Range (ATR) 0.74 2.03
MACD 0.25 -0.15
Stochastic Oscillator 71.08 33.84

Price Performance

Historical Comparison
SBGI
CSTL

About SBGI Sinclair Inc.

Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay TV distributors.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Share on Social Networks: